We studied the outcome of individuals with aplastic anaemia (AA) who received reduced-intensity conditioning followed by the infusion of stem cell grafts that had been T-cell depleted ex vivo with alemtuzumab. Consecutive patients with AA who had an HLA-identical sibling received conditioning with fludarabine 30 mg/m 2 daily for 5 days followed by CY 60 mg/kg on 2 consecutive days. Cytokine-mobilized blood grafts were incubated ex vivo with alemtuzumab 'in the bag' and infused without washing. CYA was prescribed until day þ 90. Engraftment rate, GVHD, EFS and overall survival were studied. Fifteen patients received PBPC grafts. It was the second graft in one of the patients. Ten patients were male and their median age was 23.5 years. The toxicity of the conditioning was minimal. One patient received 1 Â 10 7 /kg donor lymphocytes for rising chimerism. At a median of 1107 (294-1778) days, all of them survived with normal blood parameters. None of them developed acute or chronic GVHD. In patients with AA the combination of purine analogue and alkylator leads to rapid engraftment despite T-cell depletion of grafts. This strategy of reduced-intensity conditioning has low toxicity, does not compromise engraftment and seems effective for prevention of GVHD.
Introduction
The treatment of aplastic anaemia (AA) by SCT has evolved substantially over the last 30 years, to the point that nearly all patients survive the procedure and recover their blood parameters. The use of better immunosuppressive conditioning strategies, more effective GVHD prophylaxis and the implementation of judicious transfusion practices that minimize host exposure to allo-Ag have helped to improve treatment results. [1] [2] [3] The use of PBPC as the source of stem cells for transplantation has further reduced the post-transplant period of neutropenia and increased the fraction of surviving patients. 4 CY, given at a dose of 200 mg/kg in combination with anti-thymocyte globulin, is commonly used to condition patients with AA undergoing transplantation from a HLA-matched sibling. 3, 5, 6 However, despite immunosuppression with MTX in combination with CYA, GVHD remains the most formidable complication and leads to substantial short-and long-term morbidities and TRM. [7] [8] [9] Therefore, future improvements in the therapy of severe aplasia should focus on better prevention and control of this complication.
Depletion of T cells from the stem cell graft is the most effective strategy in prevention of GVHD, 10 even when a larger load of T cells are present, as occurs in a PBSC graft. 11, 12 Indeed, experience has revealed that with this approach the reduced incidence and severity of GVHD has been associated with improvement in the early outcome after transplantation. However, in AA this strategy has been associated with higher incidence of graft failure, but it could be overcome by more powerful immunosuppression during conditioning and by restricting the transfusion of blood products to prevent allosensitization. 1, 13 Fludarabine is a highly immunosuppressive nucleoside analogue that has been shown to be effective in the preparation of patients undergoing reduced-intensity conditioning regimens, yielding high engraftment rates with minimal conditioning-related morbidity. [14] [15] [16] [17] [18] [19] Therefore, we investigated the effectiveness of a fludarabinebased non-myeloablative conditioning combination for patients with severe aplastic anemia (SAA). We postulated that the addition of fludarabine to CY would provide supplementary host immunosuppression to help achieve engraftment in patients who, by receiving a T-cell-depleted graft with alemtuzumab (CAMPATH-1H; anti CD52 Ab), were at higher risk for graft rejection.
Patients and methods
The primary objective of this study was to determine the overall rate of engraftment and of survival for a protocol of GVHD prophylaxis by ex vivo lymphocyte depletion with alemtuzumab (CAMPATH-1H; anti CD52) in combination with post-transplant CYA in patients with AA undergoing SCT. The secondary end points were to evaluate the rate of TRM, acute or chronic GVHD, and recurrence of marrow aplasia. To this end, between May 2003 and April 2008, we recruited consecutive patients with AA referred for allogeneic transplantation from their HLAidentical siblings. Entry criteria required adequate performance status (0, 1 or 2), non-reactivity on testing for HIV and to fulfill the diagnostic criteria for severe AA. 20 To exclude Fanconi anaemia, all patients had blood samples tested for chromosomal fragility to the clastogenic agent, diepoxybutane. 21 Patients gave consent for transplantation according to the guidelines of the University of Cape Town Ethics Committee.
In preparing for the procedure a double-lumen indwelling catheter was placed into a deep thoracic vein. Before commencing preconditioning, patients received prophylaxis with oral ofloxacin 200 mg b.d., which was continued until the recovery of the neutrophil count. To prevent pneumocystis carinii and herpes simplex infections, patients received cotrimoxazole 80/400 mg daily (during conditioning and then restarted after documenting engraftment) and valocyclovir 1 g thrice daily until day 90. Patients were cared for in single-bed, laminar down-flow isolation rooms during the entire period of neutropenia. Patients developing pyrexia (438 1C) were treated with a combination of empirical i.v. piptazobactam with an aminoglycoside or a glycopeptide. If patients remained pyrexial, antibiotics were modified according to the results from microbial cultures. Fever that persisted in the absence of diagnostic serology or positive cultures indicated the addition of infusions of amphotericin deoxycholate at doses of 0.6-1 mg/kg until defervescence. After engraftment, surveillance for CMV infection was done weekly by determining the reactivity of leukocytes to the pp65 Ag. In addition, as a source of Igs, patients received weekly infusions of stabilized human serum for 3 months that were formulated to have 10% (wt/vol) Igs. 22 To maintain the Hb level 48 g/dl and the plt count 415-20 Â 10 9 /l, patients were transfused with filtered blood products that had been irradiated with 25 Gy. Patients also received tranexamic acid as antifibrinolytic agent until plt recovery. Haematopoietic growth factors were not routinely used.
Collection of stem cells for transplantation
For the mobilization of marrow progenitors, HLAidentical sibling donors were treated daily with five s.c. injections of filgrastim (G-CSF) 5-10 mg/kg/day. Largevolume apheresis was started approximately 4 h after the last dose of G-CSF. On the basis of the patients' actual body weight, the minimum target cell dose was 2 Â 10 6 CD34 þ cells/kg. In the event that this intended cell dose was not achieved, apheresis was repeated the following day. During each procedure, approximately 20-30 l of blood was processed. Thus, two donors underwent two aphereses. The volume of each apheresis unit was measured and the concentration of mononuclear cells was determined using an automated cell counter. Harvested blood mononuclear cell numbers were calculated from differential cell counts as the combination of blasts, lymphocytes and monocytes. CD34 þ progenitors were enumerated by flow cytometry according to the guidelines of the International Society for Hematotherapy and Graft Engineering using phycoerythrin-labelled CD34 Ab and FITC-labelled CD45 Ab and isotypic controls. 23 
Preparation for transplantation
Patients were prescribed allopurinol with urine alkalinization and pre-hydrated with saline solution to achieve a urinary flow of 150 ml/h. They were then conditioned with fludarabine 30 mg/m 2 on each of 5 consecutive days (total dose 150 mg) and CY (60 mg/kg, on 2 consecutive days), each with uromixetan also at 60 mg/kg, daily ( Â 2) infused in five divided doses.
Treatment with MoAb and GVHD prophylaxis
Alemtuzumab(antiCD52; CAMPATH-1H) is a humanized Ab directed against CD52, a surface Ag that is present on lymphocytes and monocytes but not on CD34 þ cells. 24 Stem-cell-rich products were incubated at a concentration of 1 mg alemtuzumab/10 10 mononuclear cells 'in the bag' and allowed to react at 20 1C for 30 min. 12, 13 Without further manipulation the cell suspension containing the Ab was then infused i.v. in sets devoid of any filters. Patients were pre-medicated with pethidine 0.1 mg/kg, phenergan 12.5 mg and 500 mg paracetamol. As further GVHD prophylaxis, starting on day À1 of transplant, patients were prescribed i.v. CYA at a dose of 3 mg/kg (in two divided doses). Once the gastrointestinal toxicity of the conditioning had recovered, CYA was taken as an oral formulation. Daily doses were adjusted to provide therapeutic blood levels (120-275 ng/ml). In the absence of GVHD, CYA was reduced by 50% per week during the last 2 weeks and stopped on day þ 90.
Engraftment and chimerism
Engraftment was defined as recovery of the granulocyte count to 40.5 Â 10 9 /l and plts to 450 Â 10 9 /l in the absence of transfusions and scored on the first of three consecutive days. Over the study period two methods of chimerism were used. Initially, to confirm engraftment at 3 months post transplantation and based on sex chromosome differences between donor and recipient we determined the origin of haematopoiesis by standard cytogenetic analysis. More recently, we determined the percentage of donor/ recipient DNA in myeloid and T-cell fractions using a PCR-based analysis of STR as described earlier. 25 
Statistical analysis
Results of patients' demographic data and characteristics of the graft were given in standard summary statistics. Disease-free survival was calculated from the time of transplantation to the time of disease recurrence, whereas overall survival was calculated from the time of transplant till the time of death from any cause and surviving patients were censored at last follow-up. Disease-free and overall survival estimates were obtained by the method of Kaplan and Meier. All data analyses were carried out using the Statistica (StatSoft Inc., Tulsa, OK) computer software package.
Results

Patient population
Fifteen patients with severe AA (Table 1 ) received reducedintensity conditioning and a PBPC graft from HLAidentical siblings that had been incubated ex vivo with alemtuzumab, an anti-CD52 MoAb. For the group the median age was 23.5 years (range 9-49). The sex distribution of the cohort included 10 males and 5 females. Their clinical characteristics are shown in Table 1 . Five patients had a major blood group mismatch with their donors and two required plasma exchange to reduce high blood Ab titer (41/32). The median time from diagnosis to transplantation was 116 days (range 62-436; one after the second transplant). CD50 and CD55 were tested in all patients and results are shown in Table 1 .
Except for one patient, all patients were extensively transfused (430 units of blood products). One of the patients had received another graft 13 months earlier following preconditioning with TBI 8 Gy, total nodal irradiation (TNI) 6 Gy and CY 120 mg/kg. 13 The stem cell graft had also been T-cell depleted with alemtuzumab. The patient had recovered his blood counts promptly, but after 7 months pancytopenia recurred and on marrow biopsy he again had features of severe marrow aplasia. Seven patients received a graft from a sex-mismatched donor. Table 1 lists the patients' characteristics before transplantation and the treatments received.
Engraftment and chimerism
The patients' clinical data post transplantation and details of the graft are presented in Table 2 . At transplantation, the median CD34 þ cell dose infused was 4.66 Â 10 6 /kg (range 1.37-16). The median dose of alemtuzumab added 'into the bag' was 9.25 mg. All patients were engrafted, including the patient who had graft failure 9 months earlier (patient 6). The median time of engraftment was 13 days (range 10-18). None of the patients developed acute or chronic GVHD.
Cytogenetic analysis at 3 months post transplantation showed the donor's karyotype exclusively in all the seven instances of gender mismatch. Chimerism studies were carried out in four patients, including one patient who developed recurrence of pancytopenia at 9 months after the first transplant (Table 2) . In this patient, the marrow Table 1 Presentation of clinical parameters of each of the patients in the study population showed aplasia (15% cellularity), whereas on STR studies 40% donor chimerism was observed. He received 1 Â 10 7 / kg CD3 donor lymphocyte infusions, and thereafter the blood parameters were normalized. In the other two patients, full donor chimerism was obtained by 1 year post transplant.
Outcome
The median follow-up was 1107 (range 294-1778) days post transplantation. At the last visit all patients had normal blood values and performance status, and no evidence of GVHD was found. Table 2 and Figure 1 show that survival is 100%, but one patient developed late recurrence of pancytopenia at 9 months, with substantial loss of donor chimerism; thus DFS was 93%. Nevertheless, in this patient normal haematopoiesis also reverted to the donor origin after the infusion of 1 Â 10 7 /kg donor CD3 cells. In seven patients with different gender donors, karyotype analysis confirmed full donor chimerism; STR analysis showed donor chimerism in another two patients.
Toxicity
The toxicity of the conditioning regimen was minimal ( Table 3) . None of the patients developed grade IV toxicities. Infusion of the graft was well tolerated; only four patients felt nausea, abdominal pain or pyrexia as a cytokine-release phenomenon. None of the patients developed veno-occlusive disease of the liver or engraftment syndrome. Two patients developed Hickman line sepsis and cultures grew Staphylococcus epidermitis infection. Another patient who had extended-spectrum b-lactamase (ESBL)-producing Klebsiella pneumoniae septicaemia underwent transplantation despite active sepsis. As the blood counts recovered, infection settled and he was discharged from hospital in good condition. Two patients developed Candida albicans septicaemia and responded to amphotericin B deoxycholate therapy. One patient developed thrombotic thrombocytopenic purpura and was treated satisfactorily with plasmapheresis. Another patient developed pure red cell aplasia unrelated to parvovirus infection but recovered after infusion of 2 g/kg of i.v. Ig. Yet another patient had haemorrhagic cystitis and the urine cultures grew BK virus. Bleeding settled after 2 weeks of conservative measures. One of the patients developed pulmonary infiltrates that failed to yield microbiological content on blood sampling and bronchial lavage. He responded to corticosteroid therapy and was discharged asymptomatic. Pulmonary infiltrates did not recur. Overall 11 patients developed fever during the transplantation period but only four had bacterial growth detected and all of them responded to empirical or directed antibiotics. One patient (7%) had reactivation of CMV and responded to gancyclovir. No delayed infections or other immune cytopenias have been reported. The current performance (Karnovsky) status for all patients is 100%.
Discussion
Over the last two decades the outcome of patients undergoing SCT for AA has improved substantially. However, even at present, graft failure, GVHD and infections remain substantial challenges. Conditioning with CY at 200 mg/kg has traditionally been prescribed for patients with severe aplasia because of relatively low toxicity and potent immunosuppressive effects. However, in heavily transfused patients it has been associated with substantial rates of graft failure. More intensified cytotoxic conditioning as well as TBI-based schedules were shown to be very effective in promoting engraftment, particularly if the first graft was rejected. 9, 13, 26 TLI was shown to be effective in inhibiting lymphocyte function and seemed to exert lower systemic morbidity with improvement in engraftment rates. 9 However, radiotherapy may not be acceptable to the mainly young population, not only due to the long-term latent risk of malignancies, 9 but also due to the substantial risk of infertility that such conditioning could cause.
The source of stem cells for transplantation remains a further point of debate. In some studies BM grafts seemed to be associated with lower rates of GVHD and mortality, 27 but this was not observed in a controlled trial. 28 Nevertheless, at least 25% of patients will develop this complication. Provided apheresis equipment is available, cytokine-mobilized stem cell grafts may be more practical as they have been associated with faster haematopoietic recovery and donors do not need a general anaesthetic for the stem cell harvest. However, pretreatment with filgrastim to BM transplant donors has also led to shortened haematopoietic recovery. 29 Although the combination of CY with anti-thymocyte globulin has shown considerable efficacy in promoting engraftment 3, 5, 6 despite standard prophylaxis with MTX and calcineurin inhibitors, with PBPC as the source of stem cells, GVHD occurs in roughly half of the patients. 9 Although the efficacy of antithymocyte globulin in preventing graft rejection is well established, and it is considered a crucial component in most mismatched transplantation regimens, 3 its role in the prevention of GVHD is more controversial. As a difference to transplantation for malignancies, GVHD would seem to add little benefit to the procedure and indeed, would seem to have undesirable toxicity. Ex vivo and in vivo T-cell depletion have been shown to be successful methods to prevent this complication, but have been associated with higher rejection rates. 30 However, if effective pre-transplant immunosuppression can be delivered, T-cell depletion would be an attractive therapeutic strategy. Of interest, purine analogues such as fludarabine were shown to exert powerful immunosuppression, allowing reduction in dose intensity of conditioning, and thus have been included in various conditioning schedules. Such combinations have favourable toxicity to efficacy ratio, particularly in elderly patients and those with co-morbidities. For this reason, we decided to test the association between fludarabine and CY in the setting of ex vivo T-cell depletion of grafts.
It was particularly satisfactory to observe in this patient population that despite extensive blood transfusion exposure and ex vivo T-cell depletion, all patients were engrafted. Indeed, in one of the successfully transplanted patients, the indication for this procedure was late graft failure despite conditioning of the first transplant (from same donor) with a radiation-based protocol. However, at 9 months after transplantation, one patient developed unstable blood counts and STR studies confirmed loss of donor chimerism, but responded to infusion of 1 Â 10 7 /kg CD3 cell. The patient recovered the blood parameters without developing any features of GVHD, and at present he has normal blood counts. This observation would suggest that patients receiving this protocol may require a more extended follow-up as delayed graft failure is still possible, so that similar action can be taken early in those with progressing mixed chimerism. Nevertheless, posttransplant karyotypic analysis in seven patients and STR testing in another two patients confirmed donor origin of haematopoiesis in each case.
The morbidity of this conditioning combination was low and a proportion of patients did not develop pyrexia during the post-transplant period, suggesting that with this strategy patients may not require sophisticated reverse isolation. At a median follow-up of 1107 days, all patients had normal blood counts. We believe that for patients receiving PBPC grafts for AA, this combined schedule of conditioning with fludarabine and CY followed by addition of low-dose CAMPATH-1H 'in the bag' and post transplant CYA seems particularly valuable, with universal engraftment, excellent prevention of GVHD and low risk of acquiring delayed opportunistic infections. Post-transplant lymphoproliferative disease was not observed, probably because CD52 is expressed on all lymphocytes and therefore alemtuzumab induced both T-cell and B-cell depletion of the PBPC graft. Indeed, in our earlier experience among patients with haematological malignancies, this complication was seen in one patient among the 81 studied. 31 It is, however, probable that some alemtuzumab was infused with the graft as PBPCs were not washed and had some in vivo activity that could have affected immune reconstitution. In another study, when alemtuzumab was injected into the patients (in vivo) at doses ranging from 0.5 to 0.75 mg/kg, it has been linked with 24% non-engraftment rate and frequent reactivation of endogenous viruses. [32] [33] [34] These higher doses of alemtuzumab used, together with a slow Ab clearance 35 characteristic of this humanized protein, seem to limit immune reconstitution and may predispose to opportunistic infections. 34 Indeed we have shown earlier that even with the ex vivo lower dose T-cell depletion, CD45 þ / CD4 þ naı¨ve cells take up to 1 year to recover, explaining an extended immunosuppression at a much higher dose. 36 For this reason we have routinely prescribed valocyclovir for 3 months to all our patients, as this agent has been associated with more favourable pharmacokinetics than acyclovir and perhaps resulted in more effective protection from CMV reactivation. 37 As marrow aplasia is a fairly rare condition, an important limitation of this study is the relatively low patient number. Thus, collaborative studies may be required to confirm this observation as T-cell depletion remains a controversial tool. However, the current results seem promising even in the context of a single-centre experience. It can therefore be concluded that conditioning with purine analogue and alkylator agents is a very effective immunosuppressive strategy, even for heavily transfused patients with marrow aplasia receiving T-cell-depleted PBPC grafts. In our experience, ex vivo T-cell depletion with alemtuzumab resulted in excellent protection from GVHD and lower rates of opportunistic infections. Therefore, prospective comparative studies with the standard conditioning of CY 200 mg/kg and anti-thymocyte globulin are warranted.
